Early Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SYNCAR-100 in the Treatment of CD19-Positive Relapsed or Refractory Acute B-Lymphoblastic Leukemia (R/R B-ALL)
Latest Information Update: 13 Mar 2026
At a glance
- Drugs SYNCAR 100 (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Bisheng (Beijing) Biotechnology
Most Recent Events
- 13 Mar 2026 New trial record